MK-626, a dipeptidyl peptidase-4 inhibitor, does not improve the hyperglycemia or hyperinsulinemia of nonobese diabetic MKR mice

Author： Bhattacharjee Alpana Allister Emma M. Wheeler Michael B.

Publisher： NRC Research Press

ISSN： 1205-7541

Source： Canadian Journal of Physiology and Pharmacology, Vol.90, Iss.5, 2012-05, pp. : 663-668

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties

By Ahrén Bo

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 4, 2006-04 ,pp. : 431-442

Informa Healthcare

Access to resources Recommend Favorite

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

By Fujii Yuki Abe Masanori Higuchi Terumi Mizuno Mari Suzuki Hiroko Matsumoto Shiro Ito Midori Maruyama Noriaki Okada Kazuyoshi Soma Masayoshi

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 3, 2013-02 ,pp. : 259-267

Informa Healthcare

Access to resources Recommend Favorite

Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes

By Stein Stephanie A Lamos Elizabeth M Davis Stephen N

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 4, 2014-04 ,pp. : 599-608

Informa Healthcare

Access to resources Recommend Favorite

Linagliptin: A Novel Methylxanthin Based Approved Dipeptidyl Peptidase-4 Inhibitor

Current Drug Targets, Vol. 13, Iss. 7, 2012-06 ,pp. : 970-983

Bentham Science Publishers

Access to resources Recommend Favorite

Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes

By Forst Thomas Pfützner Andreas

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 1, 2012-01 ,pp. : 101-110

Informa Healthcare

Access to resources Recommend Favorite